89bio (ETNB) Receives a Buy from Chardan Capital
In a report released today, Michael Morabito from Chardan Capital reiterated a Buy rating on 89bio (ETNB), with a price target of $95.00. The company’s shares closed last Monday at $36.75.
According to TipRanks.com, Morabito is a 1-star analyst with an average return of -8.3% and a 40.9% success rate. Morabito covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, NGM Biopharmaceuticals, and Viking Therapeutics.
89bio has an analyst consensus of Strong Buy, with a price target consensus of $62.40, representing a 56.8% upside. In a report issued on August 31, RBC Capital also maintained a Buy rating on the stock with a $45.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $47.25 and a one-year low of $14.00. Currently, 89bio has an average volume of 104.9K.
Based on the recent corporate insider activity of 17 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ETNB in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
89bio, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of innovative therapies for nonalcoholic steatohepatitis (NASH), liver and cardio-metabolic diseases. The company was founded on January 01, 2018 and is headquartered in San Francisco, CA.